Competitive Intelligence
1. Competitive landscape snapshot — week ending August 9
AI answers named nine alternatives to Ozempic, generating 151 total competitor mentions across 140 responses. The leading competitors were:
- Wegovy: 46
- Mounjaro: 26
- Trulicity: 25
- Zepbound: 12
- Saxenda: 12
- Rybelsus: 11
- Victoza: 10
- Bydureon: 5; Byetta: 4
Approximately 42 mentions came directly from explicitly comparative questions: Ozempic vs. Wegovy, Trulicity, Rybelsus, or Mounjaro, including the Ozempic-versus-Trulicity/Mounjaro labeling question. Roughly 109 mentions arose in answers to broader indication, dosing, visibility, substitution, or alternatives questions. This indicates that competitor framing is increasingly embedded in general Ozempic conversations, not limited to direct head-to-head prompts.
2. How the comparison is currently framed
Wegovy is the dominant reference competitor, but mostly as a category/indication counterpart rather than a direct efficacy challenger. Answers consistently say the products share semaglutide but differ in approved use and dosing: “Ozempic is approved for diabetes,” while “the weight-loss approval is for a different brand/dose (Wegovy).” This is broadly neutral, although it gives Wegovy the clearer position for chronic weight management.
Mounjaro is framed as the strongest competitive efficacy threat. Responses consistently distinguish Ozempic’s GLP-1 mechanism from Mounjaro’s dual GIP/GLP-1 mechanism and suggest tirzepatide may produce “greater appetite reduction and weight loss.” All seven Mounjaro responses paired the comparison with “stronger” or similar superiority language, though most also hedged that individual experiences vary. The net framing favors Mounjaro on weight-related outcomes.
Trulicity comparisons favor Ozempic. Six of seven responses used “stronger,” “superior,” or similar language, stating that Ozempic is perceived as more effective for weight loss and A1C reduction and that this is “not just marketing.” The answers still qualify that outcomes vary and depend on the endpoint.
Rybelsus is presented neutrally. The recurring frame is “same active ingredient, different route,” with largely overlapping warnings and route-specific differences.
3. Movers — who is gaining or losing ground
All named competitors increased in raw mentions as response volume doubled from 70 to 140. The largest gains were:
- Wegovy +23 (23→46), though its mention share slightly declined from ~32% to ~30%.
- Mounjaro +15 (11→26), share rising from ~15% to ~17%.
- Trulicity +14 (11→25), share rising to ~17%.
- Zepbound +7 (5→12) and Saxenda +8 (4→12), both gaining share.
- Rybelsus +3 (8→11), declining in share from ~11% to ~7%.
Over the five-week history, Wegovy remains the clear anchor, while Mounjaro and Trulicity have steadily strengthened. No new competitor entered this week.
4. Questions worth watching
- “Do people typically perceive Ozempic as more effective than Trulicity…?”
- “If someone switches from Ozempic to Mounjaro…?”
- “What’s the difference between Ozempic and Wegovy…?”
- “Compared with Trulicity or Mounjaro, what outcomes…are supported by Ozempic’s labeling?”
5. Recommended actions
- Track Mounjaro and Trulicity next week for sustained share growth, not just volume-driven increases.
- Flag the Mounjaro framing as a strategic watchpoint: all seven answers positioned tirzepatide as potentially stronger for weight outcomes.
- Monitor Wegovy’s role as the default weight-management reference, even as its share modestly declined.
- Maintain routine monitoring of Rybelsus; its falling share suggests no current escalation.
- Treat Ozempic’s favorable Trulicity framing as perception strength, not a broad market shift, given the limited seven-response sample.